STAT+: STAT+ Conversations: A conversation on the latest in neuroscience and CNS drug development
Editors note: A livestream of the conversation will be embedded below at 1 p.m. ET.
Sponsored By
Every week, STAT+ subscribers get access to exclusive conversations with biotech, pharma, and health tech leaders. This week, STAT senior biotech writer Adam Feuerstein will be joined by Paul Matteis, managing director and biotechnology analyst at Stifel. They will be discussing updates and impacts of current central nervous system drug development, and of course be taking your questions live.
Continue to STAT+ to read the full story…
